ライフサイエンスコーパス: multiple organ

1 tion between different endocrine systems and multiple organs.

2 was associated with greater viral burden in multiple organs.

3 ystal formation and functional impairment of multiple organs.

4 osis is an inflammatory disease that affects multiple organs.

5 idence of systemic dissemination of virus to multiple organs.

6 y massive accumulation of transformed DCs in multiple organs.

7 onic inflammation or tumors, often affecting multiple organs.

8 ing elevated glycosaminoglycans in blood and multiple organs.

9 ent function for ADAR1 in the development of multiple organs.

10 Aging is a complex process that affects multiple organs.

11 h inappropriately controlled inflammation in multiple organs.

12 kocytes, except T cells, and disseminated to multiple organs.

13 ulting in virus replication and pathology in multiple organs.

14 rominent B cell infiltration observed across multiple organs.

15 are caused by dysfunctional cilia and affect multiple organs.

16 ivity, TKT activity, and purine synthesis in multiple organs.

17 auses TSC, a benign tumor syndrome affecting multiple organs.

18 uggested as central mediators of fibrosis in multiple organs.

19 tions in the PCP genes cause malformation in multiple organs.

20 gulator of tissue repair and regeneration in multiple organs.

21 obesity treatment due to systemic effects on multiple organs.

22 r and cellular networks over time and across multiple organs.

23 ith time, and certain clones were present in multiple organs.

24 , and on pericytes and perivascular cells in multiple organs.

25 ficiency, leads to substrate accumulation in multiple organs.

26 in cilia and is required for ciliogenesis in multiple organs.

27 is, anemia, and VWF-positive microthrombi in multiple organs.

28 2, a known molecular marker of pericytes in multiple organs.

29 expression is dramatically down-regulated in multiple organs after birth but is frequently up-regulat

30 ssues, (ii) extends duration of silencing in multiple organs and (iii) protects siRNAs from 5-to-3 ex

31 ced pathogen and immune cell infiltration in multiple organs and decreased inflammatory cytokine leve

32 Many autoimmune diseases involve multiple organs and general dysfunction of the immune sy

33 Inflammation in multiple organs and heterogeneity in disease present add

34 characterized by the formation of tumors in multiple organs and is caused by germline mutation in on

35 88 and CD26 to distinguish moDCs and cDCs in multiple organs and mouse strains will facilitate studie

36 s, a phenotype observed in trNK cells across multiple organs and mouse strains.

37 s showed that EAF2 knockout caused tumors in multiple organs and prostatic intraepithelial neoplasia

38 was sufficient to induce severe fibrosis in multiple organs and steatohepatosis, which was dependent

39 factors operating during the development of multiple organs and structures.

40 myeloid-derived suppressor cells (MDSCs) in multiple organs and subsequent inflammation remain incom

41 temic expansion and infiltration of MDSCs in multiple organs and subsequent inflammation.

42 of bacteria was observed microscopically in multiple organs and tissues as early as 24 h postchallen

43 ults in spontaneous development of tumors in multiple organs and tissues.

44 asis and for the development and function of multiple organs and tissues.

45 and observed markedly decreased Mn levels in multiple organs and whole blood of both mouse models.

46 anifests as spontaneous autoimmunity against multiple organs, and 20% of patients develop an autoimmu

47 b-Cre effectively targeted myofibroblasts in multiple organs, and depletion of the alpha(v) integrin

48 CMV immunopathology, enhances MCMV burden in multiple organs, and suppresses MCMV-specific T cell mem

49 re immunopathology, enhanced viral burden in multiple organs, and suppression of MCMV-specific T cell

50 ility, epilepsy, coarse facial features, and multiple organ anomalies.

51 ome characterised by a unique combination of multiple organ anomalies.

52 is an inherited syndrome in which tumours in multiple organs are characterised by activation of mamma

53 Os) play crucial roles in the development of multiple organs as well as the survival of adult stem ce

54 uced a cohort of genes regulated by MIST1 in multiple organs but did not affect PC function.

55 al roles in the formation and homeostasis of multiple organs, but direct experiments to address the r

56 by reductions in VA levels and signaling in multiple organs, but not detected by serum VA.

57 inical management in Li-Fraumeni syndrome, a multiple-organ cancer predisposition condition, are limi

58 The result is damage to multiple organs caused by the initial cascade of inflamm

59 ted in rapid and lethal toxicities affecting multiple organs correlating with heightened proinflammat

60 t SGK1 inhibition aggravates the severity of multiple organ damage and enhances the inflammatory resp

61 In terms of the histological development of multiple organ damage and inflammatory cytokine levels i

62 metinib attenuates systemic inflammation and multiple organ damage in a clinically relevant model of

63 efects in clearing dying cells, which led to multiple organ damage indicative of immune dysfunction.

64 nished vascular inflammation, attenuation of multiple organ damage, and survival advantage in a mouse

65 Obesity increases susceptibility to multiple organ disorders, however, underlying mechanisms

66 is an essential player in the development of multiple organs during embryonic and postnatal stages.

67 ciated with defective mTORC1 inactivation in multiple organs during neonatal fasting.

68 enine 3-monooxygenase (KMO) protects against multiple organ dysfunction (MODS) in experimental acute

69 Sepsis and multiple organ dysfunction accounted for 2% of deaths.

70 ation between microcirculatory perfusion and multiple organ dysfunction after initial resuscitation.

71 various treatment modalities and support for multiple organ dysfunction in neonates and small infants

72 However, the prevalence of extracerebral multiple organ dysfunction in postcardiac arrest patient

73 eperfusion resulting from S/R contributes to multiple organ dysfunction in trauma patients.

74 ity, 28-day mortality, ventilator-free days, Multiple Organ Dysfunction Scale incidence, worst Multip

75 d, ventilator-free days increased, and worst Multiple Organ Dysfunction Scale score decreased.

76 ple Organ Dysfunction Scale incidence, worst Multiple Organ Dysfunction Scale score, and poor 6-month

77 The primary outcome was the change in Multiple Organ Dysfunction Score (MODS; range, 0 to 24,

78 days on mechanical ventilator, and Marshall Multiple Organ Dysfunction score between hypotensive and

79 organ dysfunction, reflected in a cumulative Multiple Organ Dysfunction Score greater than 25, and pa

80 The Multiple Organ Dysfunction Score is a simple organ-based

81 l the other scores with the exception of the Multiple Organ Dysfunction Score, which was significantl

82 the need for other vasoactive drugs, and the multiple organ dysfunction score.

83 II, Sequential Organ Failure Assessment, and Multiple Organ Dysfunction Scores gave area under the re

84 II, Sequential Organ Failure Assessment, and Multiple Organ Dysfunction Scores were all applied to pa

85 dentified as a target for acute pancreatitis multiple organ dysfunction syndrome (AP-MODS); a devasta

86 of sterile inflammation leading to systemic multiple organ dysfunction syndrome (MODS) and death.

87 te lung injury (ALI) is a major component of multiple organ dysfunction syndrome (MODS) following pul

88 Severe bacterial infection can cause sepsis, multiple organ dysfunction syndrome (MODS), and death.

89 temic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), and mortalit

90 storm" can lead to poor outcomes, including Multiple Organ Dysfunction Syndrome (MODS).

91 of its relationship with the development of multiple organ dysfunction syndrome (MODS).

92 ical complications, including progression to multiple organ dysfunction syndrome and even death.

93 Patients with low and medium multiple organ dysfunction syndrome experienced greater

94 llows assessment of the severity of cases of multiple organ dysfunction syndrome in the PICU with a c

95 systemic inflammatory response syndrome and multiple organ dysfunction syndrome is poorly understood

96 Multiple organ dysfunction syndrome is the main cause of

97 Multiple organ dysfunction syndrome levels were defined

98 creased respiratory rate variability for low multiple organ dysfunction syndrome patients (p < 0.05 f

99 ratory rate variability occurred in the high multiple organ dysfunction syndrome patients.

100 ty of organ dysfunction was assessed through multiple organ dysfunction syndrome scores, and sedative

101 limination of sedation in patients with high multiple organ dysfunction syndrome suggests a different

102 t of systemic inflammatory response syndrome/multiple organ dysfunction syndrome that is causal to cr

103 reatening illness characterized by shock and multiple organ dysfunction syndrome, are discussed.

104 f variation), compared to patients with high multiple organ dysfunction syndrome, who failed to mount

105 n is a key element in the development of the multiple organ dysfunction syndrome.

106 t of systemic inflammatory response syndrome/multiple organ dysfunction syndrome.

107 ld decrease hospital length of stay, prevent multiple organ dysfunction, and reduce subsequent ICU in

108 ed a 2.9 kg neonate with haemorrhagic shock, multiple organ dysfunction, and severe fluid overload fo

109 th improvement in outcomes, such as hypoxia, multiple organ dysfunction, virus clearance, and shorten

110 ogresses towards end stage renal failure and multiple organ dysfunction.

111 contributes to the pathophysiology of septic multiple organ dysfunction.

112 a promising target against sepsis-associated multiple organ dysfunction.

113 culation would improve lactate clearance and multiple organ dysfunction.

114 multicompartment "tipping points" that drive multiple organ dysfunction.

115 lymph node histopathology, and often deadly multiple organ dysfunction.

116 es during septic shock and may contribute to multiple organ dysfunction.

117 Sepsis causes multiple-organ dysfunction including pancreatic injury,

118 Complications in ICU were multiple-organ dysfunction syndrome (34%), shock (28%),

119 The clinical assessment of multiple organ dysfunctions at early stages is recognize

120 ieved, causing extensive and fatal damage to multiple organs, even at very low titers.

121 s study, we find that primary human ECs from multiple organs express the cannabinoid receptors CB1R,

122 ent; p = 0.004), especially in patients with multiple organ failure (acute-on-chronic liver failure g

123 ia, acute respiratory distress syndrome, and multiple organ failure (Denver 2 score>3) for both child

124 by the Denver multiple organ failure score), multiple organ failure (Denver multiple organ failure sc

125 ions that include fever and rash, as well as multiple organ failure (liver, kidney, lungs, and/or hea

126 olic hepatitis (AH) frequently progresses to multiple organ failure (MOF) and death.

127 Outcomes measured were mortality, multiple organ failure (MOF), venous thromboembolism, in

128 without new onset thrombocytopenia but with multiple organ failure (MOF).

129 Outcomes of interest included multiple organ failure (MOF, Marshall MOD score > 5) and

130 ced acute liver failure (n = 13), nonhepatic multiple organ failure (n = 28), chronic liver disease (

131 nfidence interval (CI): 0.09-0.55; P <0.01), multiple organ failure (OR = 0.15; 95% CI: 0.04-0.62; P

132 2.167, 95% CI: 1.234-13.140, p = 0.005), and multiple organ failure (OR = 3.067, 95% CI: 1.184-15.150

133 s thromboembolism (OR, 1.73; p < 0.001), and multiple organ failure (OR, 1.38; p = 0.02).

134 p < 0.001), endophthalmitis (p = 0.003), and multiple organ failure (p < 0.001).

135 erative intensive care stay (P = 0.014), and multiple organ failure (P < 0.001); operation before 200

136 septic shock and thrombocytopenia-associated multiple organ failure (TAMOF), and in those without new

137 rsus-host disease, and the patient died from multiple organ failure 4 months after transplantation.

138 Females had less multiple organ failure [OR: 1.18 (95% CI, 1.05-1.33); P

139 icantly smaller risk of lung dysfunction and multiple organ failure among the group receiving antipla

140 Between causes of death, multiple organ failure and brain death affected respecti

141 ciated with severe disease pathology such as multiple organ failure and cerebral malaria.

142 bolism that delays recovery or even leads to multiple organ failure and death.

143 re to develop sepsis, which may culminate in multiple organ failure and death.

144 nd chemokine interactions, which might limit multiple organ failure and decrease mortality in hemorrh

145 bundles has fortunately led to a decline in multiple organ failure and in-hospital mortality.

146 Ebola virus disease complicated by multiple organ failure can be survivable with the applic

147 Hemorrhagic shock often progresses to multiple organ failure despite conventional resuscitatio

148 ocytes are implicated in the pathogenesis of multiple organ failure in sepsis.

149 e Staphylococcus haemolyticus, septic shock, multiple organ failure including acute respiratory distr

150 There is moderate evidence that multiple organ failure is a risk factor for delirium.

151 t receiving it (lung dysfunction p = 0.0116, multiple organ failure p = 0.0291).

152 Overall, the multiple organ failure rate was 27%.

153 deteriorate and within 3 weeks had developed multiple organ failure requiring ventilation, haemofiltr

154 ilure score), multiple organ failure (Denver multiple organ failure score >3), and mortality.

155 red blood cells within 24 hours, and Denver multiple organ failure score at 72 hours as independent

156 MODS was defined as a Denver Multiple Organ Failure score of 4 or greater.

157 unction (defined as grades 2-3 by the Denver multiple organ failure score), multiple organ failure (D

158 005), greater organ failure severity (Denver multiple organ failure score, 3.5 +/- 2.4 vs 0.8 +/- 1.1

159 nd developed for severe critical illness and multiple organ failure secondary to Ebola virus infectio

160 gut ischemia leading to the exacerbation of multiple organ failure syndrome.

161 n size for mortality, sepsis, infection, and multiple organ failure was approximately 60% total body

162 One study observed an increase in multiple organ failure with higher ratios, whereas no st

163 pre-existing injury, potentially leading to multiple organ failure).

164 all, 63% developed lung dysfunction, 19% had multiple organ failure, and 21% died.

165 as well as more frequent infections, sepsis, multiple organ failure, and death (p < 0.05).

166 condition that can manifest as septic shock, multiple organ failure, and death.

167 d metabolic responses, prevalence of sepsis, multiple organ failure, and mortality than burn patients

168 cations, but mostly due to the occurrence of multiple organ failure, and occurred after a median time

169 d with a decreased risk of lung dysfunction, multiple organ failure, and possibly mortality in high-r

170 species colonization at multiple sites, and multiple organ failure, empirical treatment with micafun

171 uired sepsis, multiple Candida colonization, multiple organ failure, exposed to broad-spectrum antiba

172 nt patients, complicated by septic shock and multiple organ failure, including acute renal injury and

173 Male sex, multiple organ failure, increasing percentage of pancrea

174 included respiratory infection, sepsis, and multiple organ failure, length of stay and mortality; ad

175 Secondary outcomes were multiple organ failure, lung injury, and sepsis.

176 Males are more susceptible to multiple organ failure, sepsis, and mortality after trau

177 ent modalities, length of stay, and outcome (multiple organ failure, sepsis, mortality rates) were as

178 cluding acute respiratory distress syndrome, multiple organ failure, venous thromboembolism, sepsis,

179 nduces hyperinflammation, ultimately causing multiple organ failure.

180 er OHCA, cyclosporine does not prevent early multiple organ failure.

181 rfusion, systemic inflammatory response, and multiple organ failure.

182 of systemic inflammatory response underlying multiple organ failure.

183 pital mortality, venous thromboembolism, and multiple organ failure.

184 iver abscess, (7) endophthalmitis, , and (8) multiple organ failure.

185 the pathogenesis of critical illness-induced multiple organ failure.

186 severe trauma, which predisposes patients to multiple organ failure.

187 rfusion, systemic inflammatory response, and multiple organ failure.

188 a role in the pathophysiology of sepsis and multiple organ failure.

189 sponse to infection that often culminates in multiple organ failure.

190 ents with acute-on-chronic liver failure and multiple organ failure.

191 Most deaths occurred early after multiple organ failure.

192 ic ischemia, and the patient rapidly died of multiple organ failure.

193 ng high-dose catecholamines and had signs of multiple organ failure: pH 7.16 (6.68-7.39), blood lacta

194 atio, 0.15; 95% CI, 0.03-0.60) and new-onset multiple-organ failure (15.6% vs 39.1%; P = .008; risk r

195 h increased risk of cardiovascular death and multiple-organ failure (adjusted hazard ratio, 2.07 [1.3

196 rimarily driven by cardiovascular causes and multiple-organ failure, and may thus identify a vulnerab

197 econdary conditions such as septic shock and multiple-organ failure.

198 ndin-based 3D cultures, Lgr5 stem cells from multiple organs form ever-expanding epithelial organoids

199 basic cellular mechanisms and necessary for multiple organ function.

200 Cul9 null mice develop spontaneous tumors in multiple organs; however, both the cellular and the mole

201 Multiple organs in Bok(-/-) mice exhibited resistance to

202 rdio-cerebrovascular complications affecting multiple organs in individuals with prediabetes.

203 g enzyme, potentiates tissue regeneration in multiple organs in mice.

204 cium and phosphate homeostasis that involves multiple organs in terms of mineral flux and endocrine c

205 up 2 innate lymphoid cells (ILC2s) reside in multiple organs in the body, where they play roles in im

206 etic disease that affects the development of multiple organs in the human body.

207 This study suggests the complex interplay of multiple organs in the pathogenesis of obesity-related c

208 a subset of CD11b(+)CD11c(+)MHCII(+) MNPs in multiple organs including adipose tissues.

209 heterogeneous autoimmune condition affecting multiple organs including skin, which remains poorly und

210 Palpha), a transcription factor expressed in multiple organs including the bone marrow.

211 Loss of control of tubule lumen size in multiple organs including the kidney, liver and pancreas

212 The condition affects the development of multiple organs, including brain, kidney and skeleton.

213 KO) mice with age develop tissue fibrosis of multiple organs, including heart, liver, kidney, and lun

214 on T cells in mice promotes inflammation in multiple organs, including intestine.

215 rombophilia involving large blood vessels in multiple organs, including liver, lung, spleen, and kidn

216 ; db/db), have greatly reduced ROL levels in multiple organs, including liver, lungs, pancreas, and k

217 The axolotl can regenerate multiple organs, including the brain.

218 p malformations and hypoplasia or aplasia of multiple organs, including the craniofacial skeleton, ea

219 with pleiotropic roles in the development of multiple organs, including the eye.

220 ermeability is a feature of many diseases of multiple organs, including the gastrointestinal tract [1

221 mmon of the microdeletion syndromes, affects multiple organs, including the heart, the nervous system

222 Flow cytometric analysis of multiple organs, including the kidney, liver, lung, lymp

223 o the pathogenesis of fibrogenic diseases in multiple organs, including the kidneys, potentially by s

224 Fibrosis in multiple organs, including the liver, kidney, and lung,

225 cial for the development and size control of multiple organs, including the liver.

226 ed in the pathogenesis of diseases affecting multiple organs, including the neural tube, kidney, and

227 physiological and pathological processes in multiple organs, including the renal podocyte; however,

228 othelial barrier disruption is a hallmark of multiple organ injury (MOI).

229 Artesunate attenuated the multiple organ injury and dysfunction caused by HS.

230 Artesunate attenuated the multiple organ injury and dysfunction caused by HS.

231 Trametinib also attenuated multiple organ injury as determined by serum creatinine,

232 a circulating iron and improved survival and multiple organ injury in animals with an established pul

233 icantly different effect on canine survival, multiple organ injury, plasma iron, and cell-free hemogl

234 al cell (EC) dysfunction is a key feature of multiple organ injury, the primary cause of fatality see

235 tion to reduce the risk of postresuscitation multiple organ injury.

236 hrombocytopenia and acute renal failure with multiple organ involvement.

237 e (SCD) leads to a chronic vasculopathy with multiple organ involvement.

238 cterized by somatic stem cell dysfunction in multiple organs leading to BM failure and other pleiotro

239 acterized by seizures and tumor formation in multiple organs, mainly in the brain, skin, kidney, lung

240 sequestration of parasitized erythrocytes in multiple organs obtained during a prospective series of

241 ericytes and vascular smooth muscle cells in multiple organs of adult mouse.

242 firmed the presence of mEV71 in the sera and multiple organs of mice.

243 isease characterized by fibrosis of skin and multiple organs of which the pathogenesis is poorly unde

244 and mitochondrial DNA mutations that affect multiple organs, often including the central and periphe

245 nd results in lytic viral replication within multiple organs, often leading to severe disease.

246 Regions of interest were drawn around multiple organs on the CT scan and copied to the PET sca

247 However, its transcriptome across multiple organs, or developmental stages, has not yet be

248 -threatening autoimmune disorder, leading to multiple organ pathologies and kidney destruction.

249 ive of TSS (serum cytokine/chemokine levels, multiple organ pathology, and SAg-induced peripheral T c

250 ity to quantify anatomical phenotypes across multiple organs provides the opportunity to assess their

251 and/or lung recipients, and higher in other/multiple organ recipients (aIRR = 2.45).

252 (ACC) is a rare malignancy that can occur in multiple organ sites and is primarily found in the saliv

253 recurrent and cumulative ischemic insults to multiple organs, such as the brain.

254 ordinated physiological deterioration across multiple organ systems (e.g., pulmonary, periodontal, ca

255 It involves multiple organ systems and can cause life-threatening di

256 ECD frequently involves multiple organ systems and has historically lacked effec

257 and characterized by abnormalities spanning multiple organ systems ascertained with variable clinica

258 , the additive effect of DDAH1 expression in multiple organ systems determines plasma ADMA concentrat

259 al science point to potential targets across multiple organ systems for early intervention to improve

260 Multiple organ systems require epithelial barriers for n

261 -art, multimodality perspective spanning the multiple organ systems that contribute to cardiometaboli

262 pid and massive transcriptional responses in multiple organ systems that occur on feeding and coordin

263 r "biological aging" (declining integrity of multiple organ systems).

264 These effects have been reported in multiple organ systems, and the majority of data clearly

265 ve a complex set of physiological effects on multiple organ systems, but current understanding of the

266 they are experiencing age-related changes in multiple organ systems, including the brain, which compl

267 VHD may manifest in a single organ or affect multiple organ systems, including the mouth, eyes, and t

268 both chronic immunologic disorders involving multiple organ systems, reports about association of dis

269 morphology at single-cell resolution within multiple organ systems.

270 d be expected to lead to disorders involving multiple organ systems.

271 postnatal survival and normal functioning of multiple organ systems.

272 spectrum of clinical presentations involving multiple organ systems.

273 nserved and involved in the morphogenesis of multiple organ systems.

274 AI-1) have been shown to promote fibrosis in multiple organ systems.

275 , neuropathy, and metabolic abnormalities in multiple organ systems.

276 pread potential for hamartomatous growths in multiple organ systems.

277 rombo-occlusive vasculopathy that can affect multiple organ systems.

278 bx18 performs a vital role in development of multiple organ systems.

279 LP may impact multiple disease states within multiple organ systems.

280 percytokinemia and immune-mediated injury of multiple organ systems.

281 wide range of disease processes that include multiple organ systems.

282 essors to accelerate biological aging across multiple organ systems.

283 e embryo, contributing to the development of multiple organ systems.

284 synchronisation of internal processes across multiple organ systems.

285 ling those observed in human patients across multiple organ systems.

286 d generate more widespread disease affecting multiple organ systems.

287 ,5)-bisphosphate (PI(3,5)P2) is essential in multiple organ systems.

288 f abnormal protein glycosylation that affect multiple organ systems.

289 or studying the effects of hypothyroidism on multiple organ systems.

290 lobin have activated vascular endothelium in multiple organs that exhibits enhanced expression of NF-

291 fic effects in development and physiology of multiple organs, thereby contributing to sexual dimorphi

292 sease that presents with rapidly progressive multiple organ thromboses.

293 disease often result in severe compromise of multiple organs, tissue repair and organ function recove

294 We identified viral antigen in multiple organ tissues where it was not detected previou

295 Preemptive and multiple-organ transplants were excluded.

296 mic autoimmune diseases such as lupus affect multiple organs, usually in a diverse fashion where only

297 brafish resulted in developmental defects in multiple organs, which suggested loss of fibroblast grow

298 d disorder of lysosomal metabolism affecting multiple organs with cardiac disease being the leading c

299 these materials can image micrometastases in multiple organs with spatiotemporal resolution.

300 mic stability and prevents tissue decline in multiple organs, yet it confers ICL-induced anti-cancer